NUVB
NYSENuvation Bio Inc.
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 21 recent filings. 17 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
Sauvage Philippe Chief Financial Officer | Option exercise | 40K | $2.17 | $86,797.83 | 2026-07-15 |
Sauvage Philippe Chief Financial Officer | Option exercise | 1 | $1.97 | $1.97 | 2026-07-15 |
Sauvage Philippe Chief Financial Officer | Option exercise | 40K | $0.00 | — | 2026-07-15 |
Sauvage Philippe Chief Financial Officer | Option exercise | 1 | $0.00 | — | 2026-07-15 |
Markel Stacy CHIEF PEOPLE OFFICER | Option exercise | 90.38K | $1.87 | $169,010.60 | 2026-06-23 |
Markel Stacy CHIEF PEOPLE OFFICER | Option exercise | 34.62K | $1.74 | $60,238.80 | 2026-06-23 |
Markel Stacy CHIEF PEOPLE OFFICER | Sell (open market) | 125K | $6.03 | $753,187.50 | 2026-06-23 |
Markel Stacy CHIEF PEOPLE OFFICER | Option exercise | 90.38K | $0.00 | — | 2026-06-23 |
Markel Stacy CHIEF PEOPLE OFFICER | Option exercise | 34.62K | $0.00 | — | 2026-06-23 |
Wentworth Kerry CHIEF REGULATORY OFFICER | Option exercise | 63K | $2.93 | $184,590.00 | 2026-06-23 |
Wentworth Kerry CHIEF REGULATORY OFFICER | Sell (open market) | 63K | $6.02 | $379,190.70 | 2026-06-23 |
Wentworth Kerry CHIEF REGULATORY OFFICER | Option exercise | 63K | $0.00 | — | 2026-06-23 |
Sauvage Philippe Chief Financial Officer | Option exercise | 47.67K | $2.17 | $103,439.56 | 2026-06-23 |
Sauvage Philippe Chief Financial Officer | Sell (open market) | 47.67K | $6.01 | $286,370.28 | 2026-06-23 |
Sauvage Philippe Chief Financial Officer | Option exercise | 47.67K | $0.00 | — | 2026-06-23 |
Mashal Robert Director | Buy (open market) | 25K | $4.73 | $118,250.00 | 2026-06-09 |
VERNON W ANTHONY Director | Grant / award | 123.4K | $0.00 | — | 2026-05-21 |
Mashal Robert Director | Grant / award | 123.4K | $0.00 | — | 2026-05-21 |
FALBERG KATHRYN E Director | Grant / award | 123.4K | $0.00 | — | 2026-05-21 |
BLICKENSTAFF KIM D Director | Grant / award | 123.4K | $0.00 | — | 2026-05-21 |
Bazemore Robert B Director | Grant / award | 123.4K | $0.00 | — | 2026-05-21 |
Source: SEC EDGAR Forms 4/4A (CIK 1811063). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
$NUVB excited for this week!
$NUVB $ABBV $VRTX $NVS trade below consensus targets while holding key averages. the market may be underpricing catalysts, not deterioration https://stocksrunner.com/news/2026-08-02-value-repricing-candidates-with-technical-support
$TNXP seth clearly overpriced the drug. That is hurting us. A 60% GTN is AWFUL. My God… I wish every biotech CEO actually “got the business”. I do. David Hung at $NUVB gets it. My old friend at $BMY gets it. Heck even the $MIST CEO gets it and is fighting for their patients. Seth should stop writing terrible articles on substack and step down. 👎
$NUVB big week ahead be nice to push up over 7.50 before earnings on Thursday morning.
$NUVB added
$NUVB I’m kinda surprised with today’s action but hopefully Thursday we are above $7 and we start a march towards ATH later this year
$NUVB added
$NUVB nothing burger low volume morning....trade still intact
$NUVB wtf.. always with the drop
$NUVB let’s see if we can push for a 6.80 close
$NUVB perfect action since the offering, exactly what we wanted to see....eager for next week
$NUVB Here are the last times the Dow dropped by 1,000 points and what happened next https://www.cnbc.com/2026/07/29/the-last-times-the-dow-fell-1000-points-and-what-happened-next.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
Latest news
Nuvation Bio Inc. (NUVB) Expected to Beat Earnings Estimates: Should You Buy?
Wall Street Analysts See a 94.32% Upside in Nuvation Bio (NUVB): Can the Stock Really Move This High?
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
Nuvation Bio's Safusidenib Clinical Program, Ibtrozi Opportunity Create Favorable Setup, RBC Says
Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock?
Sector Update: Healthcare Stocks Fall Late Afternoon
Sector Update: Healthcare
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug
Nuvation Bio's Safusidenib Data Support Broader Glioma Opportunity, Wedbush Says
Nuvation Bio Says New Data Shows Safusidenib's 'Durable' Efficacy in Phase 2 IDH1-mutant Glioma Trial
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.